Daily Endocrinology Research Analysis
Analyzed 106 papers and selected 3 impactful papers.
Summary
Three standout endocrinology-related studies span mechanistic, therapeutic, and implementation insights: irisin restores β-cell function via ER calcium mobilization under glucotoxic stress; finerenone slows kidney disease progression in glomerular diseases; and real-world data identify modifiable drivers of post-exercise nocturnal hypoglycemia in type 1 diabetes, with hybrid closed-loop systems halving risk.
Research Themes
- Myokine-driven β-cell rescue mechanisms in type 2 diabetes
- Mineralocorticoid receptor antagonism in glomerular kidney disease
- Technology-enabled mitigation of exercise-related nocturnal hypoglycemia in type 1 diabetes
Selected Articles
1. The myokine irisin ameliorates the secretory dysfunction of pancreatic β cells in experimental and human type 2 diabetes.
In HFD/STZ-diabetic mice, irisin increased islet insulin content, glucose-stimulated insulin secretion, and β-cell proliferation, improving glycemia. In human T2D islets, irisin restored insulin content and GSIS. Mechanistically, under glucotoxicity irisin enhanced ER Ca2+ mobilization via AMPK–mTORC1–S6K (without CREB/AKT activation), rescuing exocytotic coupling.
Impact: This study provides mechanistic evidence in multiple systems, including human T2D islets, that irisin directly rescues β-cell function via ER Ca2+ signaling under glucotoxic stress—a potential therapeutic avenue beyond insulin sensitization.
Clinical Implications: Irisin or downstream targets (AMPK–mTORC1–S6K–ER Ca2+ axis) could be developed to preserve β-cell functional mass in T2D, complementing current glucose-lowering strategies and potentially enhancing durability of glycemic control.
Key Findings
- In HFD/STZ-diabetic mice, irisin increased islet insulin content and GSIS and markedly stimulated β-cell proliferation, improving glycemic homeostasis.
- In human islets from T2D donors, irisin restored insulin content and glucose-stimulated insulin secretion despite structural/functional impairments.
- Under chronic high glucose, irisin failed to activate CREB/AKT but enhanced AMPK–mTORC1–S6K–dependent ER Ca2+ mobilization to rescue secretion.
Methodological Strengths
- Cross-system validation: in vivo diabetic mice, human T2D islets ex vivo, and β-cell line mechanistic assays
- Clear pathway dissection linking AMPK–mTORC1–S6K to ER Ca2+ mobilization under glucotoxicity
Limitations
- Preclinical nature; efficacy and safety of irisin in humans remain untested in controlled trials
- Donor numbers and heterogeneity for human islets not detailed; long-term β-cell durability not assessed
Future Directions: Test irisin or pathway agonists in large-animal diabetes models, quantify human islet donor response heterogeneity, and design early-phase trials targeting AMPK–mTORC1–S6K–ER Ca2+ signaling to preserve β-cell function.
Irisin is a myokine that enhances insulin secretion and β cell viability in both rodent and human β cells. Here, we investigated whether irisin preserves β cell functional mass in vivo in diabetic mice and ex vivo in human pancreatic islets from subjects with type 2 diabetes (T2D). In mice made diabetic by a high-fat diet and streptozotocin, irisin administration improved glycemic homeostasis by increasing islet insulin content and glucose-stimulated insulin secretion while also markedly stimulating β cell proliferation. In islets from T2D subjects, which typically display substantial structural and functional impairments, irisin restored insulin content and glucose-stimulated insulin secretion. Mechanistic studies in INS-1E cells showed that chronic exposure to high glucose blunted glucose-triggered cytoplasmic calcium increases, essential for insulin secretion. Under these glucotoxic conditions, while irisin was unable to activate CREB and AKT, it induced AMPK-mTORC1-S6K-dependent mobilization of endoplasmic reticulum calcium stores, resulting in enhancement of insulin secretion. Overall, these findings highlight irisin's multifaceted ability to counteract β cell failure in experimental and human T2D.
2. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.
Among 903 participants with glomerular diseases, finerenone slowed eGFR decline (difference 0.73 mL/min/1.73 m2/yr), reduced albuminuria by 42% at 12 months, and lowered kidney failure or ≥40% eGFR decline (HR 0.74). Safety was consistent with prior trials.
Impact: Provides randomized, double-blind evidence supporting finerenone in a broad set of glomerular diseases, extending benefits beyond diabetic CKD and informing guideline discussions.
Clinical Implications: Finerenone can be considered to slow progression and reduce albuminuria in glomerular diseases (e.g., IgA nephropathy, FSGS, membranous nephropathy) on top of standard care, with monitoring akin to prior CKD indications.
Key Findings
- Total eGFR slope to 32 months: −3.50 with finerenone vs −4.23 mL/min/1.73 m2/yr with placebo (difference 0.73; 95% CI 0.22–1.24).
- Albuminuria reduced by 42% at month 12 (95% CI 35%–48%) with finerenone.
- Composite kidney failure or ≥40% eGFR decline reduced: 7.42 vs 9.60 events/100 patient-years; HR 0.74 (95% CI 0.57–0.97).
Methodological Strengths
- Randomized, double-blind, placebo-controlled phase 3 framework with prespecified subgroup analysis
- Large multinational cohort with consistent calibration and clinically meaningful endpoints
Limitations
- Exploratory subgroup analysis; not powered primarily for each disease subtype
- Investigator-reported diagnoses and heterogeneity across glomerulopathies may limit disease-specific inferences
Future Directions: Disease-specific RCTs and pragmatic trials assessing finerenone across glomerulopathy subtypes with biomarker stratification (e.g., proteinuria levels, fibrosis markers) and longer-term hard outcomes.
IMPORTANCE: Glomerular diseases are a leading cause of chronic kidney disease (CKD) and kidney failure. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of kidney function loss in CKD, but its effects in individuals with CKD due to glomerular diseases are uncertain. OBJECTIVES: To evaluate the efficacy and safety of finerenone in patients with glomerular diseases. DESIGN, SETTING, AND PARTICIPANTS: Prespecified exploratory subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled trial conducted across 24 countries and regions, focusing on participants with an investigator-reported glomerular disease diagnosis. The overall trial enrolled adults with nondiabetic CKD and an estimated glomerular filtration rate (eGFR) of either (1) at least 25 to less than 60 mL/min/1.73 m2 and urinary albumin to creatinine ratio of at least 200 mg/g to less than 500 mg/g or (2) an eGFR of at least 25 to less than 90 mL/min/1.73 m2 and urinary albumin to creatinine ratio of at least 500 mg/g to less than 3500 mg/g. INTERVENTION: Finerenone 10 mg or 20 mg taken orally once daily (n = 446) vs matching placebo (n = 457). MAIN OUTCOMES AND MEASURES: Annualized rate of eGFR decline (total eGFR slope) from baseline to month 32 (primary outcome of the main trial); percent change in albuminuria to 12 months; and a composite outcome of kidney failure or sustained 40% or more decline in eGFR (prespecified exploratory outcomes).
3. Factors Associated With Nocturnal Hypoglycemia After Exercise in the Type 1 Diabetes and Exercise Initiative (T1DEXI) Study.
In 496 adults across 12,340 nights, exercise days increased level 1 nocturnal hypoglycemia (15.6% vs 13.1%). Pre-exercise TBR ≥4% doubled risk; higher pre-exercise/bedtime glucose and avoiding hypoglycemia during/within 4 h post-exercise reduced risk. Hybrid closed-loop approximately halved nocturnal hypoglycemia versus standard pumps/MDI.
Impact: Delivers actionable, real-world guidance to mitigate a key barrier to exercise in type 1 diabetes, quantifying benefits of hybrid closed-loop and pre-exercise glucose strategies.
Clinical Implications: Recommend hybrid closed-loop where available; target slightly higher pre-exercise and bedtime glucose, minimize time-below-range before exercise (<4%), and avoid hypoglycemia during/4 h after exercise to reduce nocturnal events.
Key Findings
- Exercise days had more level 1 nocturnal hypoglycemia than sedentary days (15.6% vs 13.1%; P=0.001).
- Pre-exercise TBR ≥4% vs <4% markedly increased risk (level 1: 22.9% vs 11.7%; level 2: 10.2% vs 3.3%; both P<0.001).
- Hybrid closed-loop users had about half the nocturnal hypoglycemia rates vs standard pumps or MDI (level 1: 9.7% vs 20.3% vs 17.3%; level 2: 3.2% vs 7.2% vs 5.8%; both P<0.001).
Methodological Strengths
- Large real-world prospective cohort with 12,340 nights of CGM data
- Direct comparison of exercise vs sedentary nights and device stratification
Limitations
- Observational design susceptible to residual confounding (exercise type/intensity, behavioral factors)
- Short-term nightly assessments; not randomized to device or behavioral strategies
Future Directions: Randomized trials of pre-exercise glucose targets and algorithm tweaks in hybrid closed-loop, and stratified protocols by exercise intensity/type to refine guidance.
OBJECTIVE: To identify modifiable factors associated with postexercise nocturnal hypoglycemia in the Type 1 Diabetes and Exercise Initiative (T1DEXI) study. RESEARCH DESIGN AND METHODS: In this real-world prospective cohort study, overnight continuous glucose monitoring data following exercise days versus sedentary days were assessed in adults with type 1 diabetes. Nocturnal hypoglycemia was defined as a continuous glucose monitoring level of 54-69 mg/dL (level 1) or <54 mg/dL (level 2) for ≥15 min between midnight and 6:00 a.m. RESULTS: Among 496 adults across 12,340 nights, exercise days were associated with more frequent level 1 nocturnal hypoglycemia relative to sedentary days (15.6% vs. 13.1%, P = 0.001). Factors associated with reduced risk included lower preexercise time below range, higher preexercise and bedtime glucose, absence of hypoglycemia during or within 4 h after exercise, and hybrid closed-loop delivery. Time below range ≥4% in the 24 h preceding exercise was associated with substantially higher nocturnal hypoglycemia risk relative to <4% for level 1 (22.9% vs. 11.7%) and level 2 (10.2% vs. 3.3%) (both P < 0.001). Hybrid closed-loop users experienced approximately half the rate of nocturnal hypoglycemia compared with participants using standard pumps or multiple daily injections (level 1: 9.7% vs. 20.3% vs. 17.3%, respectively; level 2: 3.2% vs. 7.2% vs. 5.8%, respectively) (both P < 0.001). CONCLUSIONS: In the T1DEXI study, exercise was associated with increased nocturnal hypoglycemia risk in adults with type 1 diabetes. Targeting modifiable factors may reduce risk and address a critical barrier to safe physical activity in type 1 diabetes.